Citations

Clear

4847 citation(s) found for "Yu, Eric".

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
Susswein, Lisa R. , Roberts, Maegan E. , Yang, Hana , Marshall, Megan L. , Hiraki, Susan , Berkofsky‐Fessler, Windy, Gupta, Sounak , Shen, Wei , Dunn, Carolyn, Huang, Huaizhi , Yadav, Siddhartha , Hruska, Kathleen S. , Chen, Chen , Lumby, Carolyn A. , Hu, Chunling , Hiraki, Susan , Gupta, Sounak , Shen, Wei , Dunn, Carolyn A, Na, Jie , Domchek, Susan M , Yadav, Siddhartha , Monteiro, Alvaro N , Hart, Steven N , Couch, Fergus J. , Chen, C , Huang, Huaizhi , Lumby, Carolyn A , Roberts, Maegan E , Hu, Chunling , Na, Jie , Domchek, Susan M. , Monteiro, Álvaro N.A. , Polley, Eric C. , Hart, Steven N. , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | June 23, 2022 | Volume: 28 | Issue: 17 | Pages: 3742-3751

10.1158/1078-0432.ccr-22-0203 | PMID 35736817 Get It

Abstract Purpose: The identification of variants of uncertain significance (VUS) in the BRCA1 and BRCA2 genes by hereditary cancer testing poses great challenges for the clinical management of variant carriers. The ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) variant classification framework, which incorporates multiple sources of evidence, has the potential to establish the clinical relevance of many VUS. We sought to classify the clinical relevance of 133 single-nucleotide substitution variants encoding missense variants in the DNA-binding domain (DBD) of BRCA2 by incorporating results from a validated functional assay into an ACMG/AMP-variant classification model from a hereditary cancer–testing laboratory. Experimental Design: The 133 selected VUS were evaluated using a validated homology-directed double-strand DNA break repair (HDR) functional assay. Results were combined with clinical and genetic data from variant carriers in a rules-based variant classification model for BRCA2. Results: Of 133 missense variants, 44 were designated as non-functional and 89 were designated as functional in the HDR assay. When combined with genetic and clinical information from a single diagnostic laboratory in an ACMG/AMP-variant classification framework, 66 variants previously classified by the diagnostic laboratory were correctly classified, and 62 of 67 VUS (92.5%) were reclassified as likely pathogenic (n = 22) or likely benign (n = 40). In total, 44 variants were classified as pathogenic/likely pathogenic, 84 as benign/likely benign, and 5 remained as VUS. Conclusions: Incorporation of HDR functional analysis into an ACMG/AMP framework model substantially improves BRCA2 VUS re-classification and provides an important tool for determining the clinical relevance of individual BRCA2 VUS.
Diagnostic Performance in Low- and High-Contrast Tasks of an Image-Based Denoising Algorithm Applied to Radiation Dose–Reduced Multiphase Abdominal CT Examinations
Voß, Benjamin, Lee, Nam Ju, Takahashi, Hiroaki , Kozaka, Kazuto , Heiken, Jay P. , Ehman, Eric C. , Vasconcelos, Rogerio N., Fidler, Jeff L. , Lee, Yong S. , Mileto, Achille , Johnson, Matthew P. , Baer‐Beck, Matthias, Weber, Nikkole M. , Michalak, Gregory J. , Halaweish, Ahmed F., Carter, Rickey E. , Inoue, Akitoshi , Voss, Benjamin A, Vasconcelos, Rogerio, Halaweish, Ahmed, Carter, Rickey E , Takahashi, Hiroaki , Lee, Nam Ju, Fidler, Jeff L. , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | June 22, 2022 | Volume: 220 | Issue: 1 | Pages: 73-85

10.2214/ajr.22.27806 | PMID 35731096 Get It

Pathogenic mutations in the chromokinesin KIF22 disrupt anaphase chromosome segregation
Thompson, Alex F. , Blackburn, Patrick R. , Arons, Noah S, Stevens, Sarah N, Babovic‐Vuksanovic, Dusica , Lian, Jane B. , Klee, Eric W. , Stumpff, Jason , Klee, Eric W

Mayo Clinic

eLife | June 22, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.78653 | PMID 35730929 Get It

The chromokinesin KIF22 generates forces that contribute to mitotic chromosome congression and alignment. Mutations in the α2 helix of the motor domain of KIF22 have been identified in patients with abnormal skeletal development, and we report the identification of a patient with a novel mutation in the KIF22 tail. We demonstrate that pathogenic mutations do not result in a loss of KIF22’s functions in early mitosis. Instead, mutations disrupt chromosome segregation in anaphase, resulting in reduced proliferation, abnormal daughter cell nuclear morphology, and, in a subset of cells, cytokinesis failure. This phenotype could be explained by a failure of KIF22 to inactivate in anaphase. Consistent with this model, constitutive activation of the motor via a known site of phosphoregulation in the tail phenocopied the effects of pathogenic mutations. These results suggest that the motor domain α2 helix may be an important site for regulation of KIF22 activity at the metaphase to anaphase transition. In support of this conclusion, mimicking phosphorylation of α2 helix residue T158 also prevents inactivation of KIF22 in anaphase. These findings demonstrate the importance of both the head and tail of the motor in regulating the activity of KIF22 and offer insight into the cellular consequences of preventing KIF22 inactivation and disrupting force balance in anaphase.
Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants
Greenberg, Rachel G. , McDonald, Scott A. , Tanaka, David , Jensen, Erik A. , Meurs, Krisa P. Van , Eichenwald, Eric C. , Duncan, Andrea, Walsh, Michele C. , Das, Abhik , Cotten, C. Michael , Brumbaugh, Jane E. , Das, Abhik , Laughon, Matthew Maxwell , Duncan, Andrea F.

Mayo Clinic

Archives of Disease in Childhood - Fetal and Neonatal Edition | June 21, 2022 | Volume: 107 | Issue: 6 | Pages: 638-643

10.1136/archdischild-2021-323573 | PMID 35728925 Get It

Objective Develop an online estimator that accurately predicts bronchopulmonary dysplasia (BPD) severity or death using readily-available demographic and clinical data. Design Retrospective analysis of data entered into a prospective registry. Setting Infants cared for at centres of the United States Neonatal Research Network between 2011 and 2017. Patients Infants 501–1250 g birth weight and 23 0/7–28 6/7 weeks’ gestation. Interventions None. Main outcome measures Separate multinomial regression models for postnatal days 1, 3, 7, 14 and 28 were developed to estimate the individual probabilities of death or BPD severity (no BPD, grade 1 BPD, grade 2 BPD, grade 3 BPD) defined according to the mode of respiratory support administered at 36 weeks’ postmenstrual age. Results Among 9181 included infants, birth weight was most predictive of death or BPD severity on postnatal day 1, while mode of respiratory support was the most predictive factor on days 3, 7, 14 and 28. The predictive accuracy of the models increased at each time period from postnatal day 1 (C-statistic: 0.674) to postnatal day 28 (C-statistic 0.741). We used these results to develop a web-based model that provides predicted estimates for BPD by postnatal day. Conclusion The probability of BPD or death in extremely preterm infants can be estimated with reasonable accuracy using a limited amount of readily available clinical information. This tool may aid clinical prognostication, future research, and center-specific quality improvement surrounding BPD prevention. Trial registration number NCT00063063
Major adverse cardiovascular events after diagnosis of myocardial injury and types 1 and 2 myocardial infarction
Knott, Jonathan D , Ola, Olatunde , Akula, Ashok , Mehta, Ramila A. , Dworak, Marshall , Crockford, Erika, Lobo, Ronstan , Rastas, Nicholas, Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Grube, Eric , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Jaffe, Allan S. , Sandoval, Yader , Sandoval, Yader , Michieli, Laura De , Grube, Eric, Jaffe, Allan S.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | June 18, 2022 | Volume: 11 | Issue: 7 | Pages: 546-557

10.1093/ehjacc/zuac075 | PMID 35715942 Get It

Abstract Aims Limited US outcome data exist among patients with myocardial injury and types 1 and 2 myocardial infarction (MI) evaluated with high-sensitivity cardiac troponin (hs-cTn). Methods and results This is an observational US cohort study of emergency department (ED) patients undergoing hs-cTnT measurement. Cases with ≥1 hs-cTnT increase >99th percentile were adjudicated following the Fourth Universal Definition of MI. Post-discharge major adverse cardiovascular events (MACE) included death, MI, heart failure (HF) hospitalization, stroke or transient ischaemic attack, and new-onset atrial fibrillation or flutter during 2 years follow-up. Among 2002 patients, 857 (43%) had ≥1 hs-cTnT >99th percentile. Among these, 702 (81.9%) had myocardial injury, 64 (7.5%) had type 1 MI, and 91 (10.6%) had type 2 MI. Compared with patients without myocardial injury, type 2 MI [8.4 vs. 50%; adjusted hazard ratio (HR) 2.31, 95% confidence interval (CI) 1.49–3.58] and myocardial injury (8.4 vs. 47%; adjusted HR 3.13, 95% CI 2.39–4.09) had a higher risk of MACE, in large part because of death and HF hospitalizations. Compared with patients with type 1 MI, type 2 MI (23 vs. 50%; adjusted HR 2.24; 95% CI 1.23–4.10) and myocardial injury (23 vs. 47%; adjusted HR 2.02; 95% CI 1.20–3.40) also have a higher risk of MACE. Conclusion Among unselected US ED patients undergoing hs-cTnT measurement, most increases are due to myocardial injury, and type 2 MI is more frequent than type 1 MI. Patients with myocardial injury and type 2 MI have morbid outcomes, in large part due to death and HF.
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Thompson, Kevin J. , Leon‐Ferre, Roberto A. , Zahrieh, David , Metzger, Filho Otto, Sikov, William M. , Liu, Minetta C. , Carter, Jodi M. , Klee, Eric W. , Weinshilboum, Richard M. , Wang, Liewei , Zahrieh, David M. , Ingle, James N. , Goetz, Matthew P , Kalari, Krishna R , Thompson, Kevin J , Carter, Jodi , Sinnwell, Jason P. , Suman, Vera J. , Asad, Sarah , Stover, Daniel G. , Carey, Lisa A. , Weinshilboum, Richard M. , Boughey, Judy C. , Couch, Fergus J. , Goetz, Matthew P. , Kalari, Krishna R.

Mayo Clinic

NAR Cancer | June 17, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/narcan/zcac018 | PMID 35734391 Get It

Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor (LAR) is the most consistently identified TNBC subtype, but the clinical utility has yet to be established. Here, we constructed a novel genomic classifier, LAR-Sig, that distinguishes the LAR subtype from other TNBC subtypes and provide evidence that it is a clinically distinct disease. A meta-analysis of seven TNBC datasets (n = 1086 samples) from neoadjuvant clinical trials demonstrated that LAR patients have significantly reduced response (pCR) rates than non-LAR TNBC patients (odds ratio = 2.11, 95% CI: 1.33, 2.89). Moreover, deconvolution of the tumor microenvironment confirmed an enrichment of luminal epithelium corresponding with a decrease in basal and myoepithelium in LAR TNBC tumors. Increased immunosuppression in LAR patients may lead to a decreased presence of cycling T-cells and plasma cells. While, an increased presence of myofibroblast-like cancer-associated cells may impede drug delivery and treatment. In summary, the lower levels of tumor infiltrating lymphocytes (TILs), reduced immune activity in the micro-environment, and lower pCR rates after NAC, suggest that new therapeutic strategies for the LAR TNBC subtype need to be developed.
Arthroscopic release of the pectoralis minor tendon from the coracoid for pectoralis minor syndrome
Haeni, David, Esper, Ronda , Hassan, Bassem T. El, Sánchez‐Sotelo, Joaquín , Martinez-Catalan, Natalia, Esper, Ronda N, El Hassan, Bassem T, Sanchez-Sotelo, J. , Martínez‐Catalán, Natalia , Wagner, Eric R.

Mayo Clinic

Journal of Experimental Orthopaedics | June 17, 2022 | Volume: 9 | Issue: 1 | Pages: No page available

10.1186/s40634-022-00491-x | PMID 35713735 Get It

AbstractPurposeThe term “pectoralis minor syndrome” refers to this constellation of symptoms that can occur when the pectoralis minor (Pm) is shortened and contracted. Release of the tendon of the Pm from the coracoid has been reported to provide substantial clinical improvement to patients presenting with pectoralis minor syndrome. The purpose of this study was (1) to describe the technique for endoscopic release of pectoralis minor tendon at the subdeltoid space, (2) to classify the pectoralis minor syndrome according to its severity and (3) and to report the short‐term outcomes of this procedure in a consecutive series of patients diagnosed with pectoralis minor syndrome.MethodsEndoscopic release of the pectoralis minor tendon was performed in a series of 10 patients presenting with pectoralis minor syndrome. There were six females and four males with a median age at the time of surgery of 42 (range from 20 to 58) years. Four shoulders were categorized as grade I (scapular dyskinesis), and six as grade II (intermittent brachial plexopathy). Shoulders were evaluated for pain, motion, satisfaction, subjective shoulder value (SSV), quick‐DASH, ASES score, and complications. The mean follow‐up time was 19 (range, 6 to 49) months.ResultsArthroscopic release of the tendon of the Pm led to substantial resolution of pectoralis minor syndrome symptoms in all but one shoulder, which was considered a failure. Preoperatively, the median VAS for pain was 8.5 (range, 7–10) and the mean SSV was 20% (range, 10% ‐ 50%). At most recent follow‐up the mean VAS for pain was 1 (range, 0–6) and the mean SSV 80% (range, 50% ‐ 90%). Before surgery, mean ASES and quick‐DASH scores were 19.1 (range, 10–41.6) and 83.1 (range, 71 and 95.5) points respectively. At most recent follow‐up, mean ASES and quick‐DASH scores were 80.1 (range, 40–100) and 19.3 (range, 2.3–68) points respectively. No surgical complications occurred in any of the shoulder included in this study.ConclusionsEndoscopic release of the tendon of the pectoralis minor from the coracoid improves pain, function and patient reported outcomes in the majority of patients presenting with the diagnosis of isolated pectoralis minor syndrome.
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Hasanov, Elshad , Yeboa, D.N. , Tucker, Mathew D., Swanson, Todd A. , Ene, Chibawanye , Hasanov, Merve , Derks, Sophie H. A. E. , Smits, Marion , Dudani, Shaan , Heng, Daniel Y.C., Bex, Axel , Hanalıoğlu, Şahin , Weinberg, Jeffrey S. , Hirsch, Laure , Carlo, Maria I. , Aizer, Ayal A. , Brown, Paul D. , Bilen, Mehmet Asım , Chang, Eric L. , Jaboin, Jerry J. , Choueiri, Toni K. , Halasz, Lia M. , Patel, Toral , Soltys, Scott G. , Elder, J. Bradley , Başkaya, Mustafa K. , Timmerman, Robert , Kim, Michelle Miran, Mut, Melike , Beal, Kathryn , Lang, Frederick F. , Giles, Rachel , Patel, Toral , Brown, Paul David, Choueiri, Toni K , Smits, Marion , Hanalioglu, Sahin , Patel, Toral R , Beckham, Thomas Hendrix , Rini, Brian I. , Brastianos, Priscilla K. , Brugarolas, James , Atkins, Michael B. , McGregor, Bradley A. , McDermott, David F. , Yu, James B. , Kim, Michelle H. , Markert, James M. , Tannir, Nizar , Samandouras, George , Jonasch, Eric W.

Mayo Clinic

CA: A Cancer Journal for Clinicians | June 16, 2022 | Volume: 72 | Issue: 5 | Pages: 454-489

10.3322/caac.21729 | PMID 35708940 Get It

Abstract Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their overall poor prognosis. Current data support a multimodal treatment strategy with radiation treatment and/or surgery. Nonetheless, the optimal approach for the management of brain metastases from renal cell carcinoma remains unclear. To improve patient care, the authors sought to standardize practical management strategies. They performed an unstructured literature review and elaborated on the current management strategies through an international group of experts from different disciplines assembled via the network of the International Kidney Cancer Coalition. Experts from different disciplines were administered a survey to answer questions related to current challenges and unmet patient needs. On the basis of the integrated approach of literature review and survey study results, the authors built algorithms for the management of single and multiple brain metastases in patients with renal cell carcinoma. The literature review, consensus statements, and algorithms presented in this report can serve as a framework guiding treatment decisions for patients. CA Cancer J Clin. 2022;72:454‐489.
Abstract 6274: Prognostic impact of Sarcopenia on clinical outcomes in advanced hepatocellular carcinoma (HCC) treated with systemic therapy
Botrus, Gehan , Akce, Mehmet , Chang, Isabela , Mesbah, Zhubene , Yancey, Eric, Blezek, Daniel J. , Klug, Jason R. , Khalil, Lana , Raman, Puneet , Ahn, Daniel H. , Usón, Pedro Luiz Serrano , Kosiorek, Heidi , Klug, Jason, Sonbol, Mohamad Bassam , Borad, Mitesh J. , Bekaii‐Saab, Tanios

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 6274-6274

10.1158/1538-7445.am2022-6274 Get It

Abstract Background: Sarcopenia is one of the early pathological features of cancer cachexia, yet the effect of sarcopenia on clinical outcomes in patients with advanced HCC is unclear. Our objective was to determine the effect of Sarcopenia on response to systemic therapy with advanced HCC. Methods: Patients with unresectable and advanced liver cancer were retrospectively evaluated between 2010 to 2019. Skeletal muscle area (SMA) was computed with a previously validated computed tomography (CT) body composition AI algorithm. The skeletal muscle index (SMI) was derived from the skeletal muscle area (SMA) (cm2) divided by patient height (m2) calculated from images at the level of L3 on pretreatment CT. Sarcopenia cutoffs for females was less than 39 cm2/m2 SMI or less than 50 cm2/m2 SMI for males. Patients’ demographics, systemic treatment response, toxicity, progression-free survival (PFS) and overall survival (OS) were compared between first-line therapy groups. Kaplan-Meier and Cox proportional hazards regression were used for survival analysis comparisons. Results: A total of 146 patients with advanced HCC were assessed from Mayo Clinic Arizona and Emory University. Seventy-six patients received immunotherapy as first-line treatment and seventy patients received TKI as first-line therapy. Sarcopenia at baseline was assessed in a total of 91 patients at first-line systemic treatment: n=48 with immunotherapy (IO) and n=43 with tyrosine kinase inhibitor (TKI). Sarcopenia was more prevalent in male patients (p=0.009), and in patients with low BMI (p=0.02). When comparing those with sarcopenia at baseline, higher response rate was observed in patients treated with IO without sarcopenia (47% versus 15%, p=0.019), this was not observed in TKI group. Interestingly, median PFS and OS was not significantly changed in patients with or without sarcopenia treated with IO or TKI on first-line therapy. Conclusions: Sarcopenia was associated with reduced response rate (RR) in patients treated with IO, but not in TKI groups. Both didn’t translate into deleterious effect in PFS and or OS. Further research with sufficient adjustments for confounding factors is warranted to better elucidate the prognostic value of sarcopenia in these patients. Citation Format: Gehan Botrus, Pedro Luiz Serrano Uson Junior, Heidi Kosiorek, Mehmet Akce, Isabela Chang, Zhubene Mesbah, Eric Yancey, Daniel Blezek, Jason Klug, Lana Khalil, Puneet Raman, Mohamad Sonbol, Mitesh Borad, Daniel Ahn, Tanios Bekaii-Saab. Prognostic impact of Sarcopenia on clinical outcomes in advanced hepatocellular carcinoma (HCC) treated with systemic therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6274.